Drug · DIN 02516721
RIZATRIPTAN
Authorized, not yet reported as sold
Authorized for sale in Canada; the company has not yet told Health Canada that it is on the market.
Status Approved since June 11, 2021.
- Drug Identification Number (DIN)
- 02516721
- Company (DIN owner)
- Sanis Health Inc.Brampton, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Rizatriptan N02CC04
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RIZATRIPTAN (RIZATRIPTAN BENZOATE) | 5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- June 11, 2021: NOC 26047Abbreviated New Drug Submission (ANDS) · Licensing agreement between two companies
Other DINs named RIZATRIPTAN
- DIN 02516756 · Marketed
- DIN 02409399 · Approved
- DIN 02409402 · Approved